AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00652158
Drug: MLN8054
RxNorm normalized name: MLN8054
DrugBank: MLN8054 (DB13061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days
Trial: NCT00136955
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
Trial: NCT00924287
Drug: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720,000 IU/kg every 8 hours for a maximum of 15 doses
Trial: NCT00924287
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Trial: NCT00924287
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
Trial: NCT02159248
Drug: Tolfenamic acid + gemcitabine + radiation
RxNorm normalized name: Tolfenamic acid
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Trial: NCT02002221
Drug: Vildagliptin (LAF237)
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
Trial: NCT01613417
Drug: gadoteridol
RxNorm normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ProHance 0.1 mmol/kg
Trial: NCT03457753
Drug: Riluzole Oral Soluble Film
RxNorm normalized name: riluzole Oral Film
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
Trial: NCT03177668
Drug: YS110
RxNorm normalized name: Yttrium Y 90 ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous administration
Trial: NCT04050865
Drug: Dexamethasone, 0.4mg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ophthalmic Insert
Trial: NCT01466985
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
Trial: NCT00175825
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
Trial: NCT00977353
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-60 mg/day, oral, for 6 weeks
Trial: NCT00977353
Drug: sarcosine
RxNorm normalized name: Sarcosine
DrugBank: Sarcosine (DB12519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-1500 mg/day, oral, for 6 weeks
Trial: NCT01009931
Drug: 12-O-tetradecanoylphorbol-13-acetate
RxNorm normalized name: 12-o-tetradecanoylphorbol-13-acetate
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
Trial: NCT01009931
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
Trial: NCT01009931
Drug: Choline magnesium trisalicylate
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline magnesium trisalicylate (DB01401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles.
Trial: NCT01719835
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 IV Days 1, 8, 15 every 28 days
Trial: NCT01719835
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4mg/m2 (max 2mg) IV every 21 days
Trial: NCT01719835
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg oral or IV Days 1-5 every 28 days
Trial: NCT01719835
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/m2 IV Day 15 every 28 days
Trial: NCT01613417
Drug: gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadovist/Gadavist 0.1 mmol/kg
Trial: NCT03412266
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
Trial: NCT03722927
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
Trial: NCT03722927
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
Trial: NCT03206320
Drug: Lidocaine Topical
RxNorm normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
Trial: NCT01128959
Drug: Intravenous Carbamazepine (IV CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
Trial: NCT00764166
Drug: Docetaxel + hormonal treatment (LH-RH agonist)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally
Trial: NCT00764166
Drug: Hormonal treatment (LH-RH agonist)
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
Trial: NCT01544322
Drug: ME-344
RxNorm normalized name: ME-344
DrugBank: ME-344 (DB13062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Trial: NCT01471054
Drug: Ozurdex
RxNorm normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema.
Trial: NCT01471054
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
Trial: NCT02002221
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.
Trial: NCT02002221
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients continued their prescribed metformin dose, if applicable.
Trial: NCT05372224
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 IU were administrated once a day for 3 months.
Trial: NCT00944541
Drug: maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
Trial: NCT00237120
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01481974
Drug: Treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design.
Trial: NCT00495144
Drug: TH-302
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02052687
Drug: LFX453 L1
RxNorm normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFX453 low dose cream 1
Trial: NCT02052687
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream
Trial: NCT00259116
Drug: Relaxin
RxNorm normalized name: Relaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00293761
Drug: Travoprost, Investigational
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in study eye once daily for 13 days
Trial: NCT00293761
Drug: Travoprost (TRAVATAN)
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in study eye once daily for 13 days
Trial: NCT02530502
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00942084
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
Trial: NCT03087890
Drug: Cotrimoxazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
Trial: NCT00859937
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03744026
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose of carboplatin infusion is AUC4-6
Trial: NCT00192959
Drug: Xenon vs propofol
RxNorm normalized name: xenon
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01271244
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20mg daily for 12 weeks
Trial: NCT00615030
Drug: Indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
Trial: NCT00615030
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 µg twice daily delivered via dry powder inhaler (DPI)
Trial: NCT00615030
Drug: Placebo to Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo matching indacaterol was delivered via SDDPI.
Trial: NCT00615030
Drug: Placebo to Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo matching salmeterol was delivered via DPI
Trial: NCT02563938
Drug: AK001
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given parenterally.
Trial: NCT00107003
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06333054
Drug: Pyrethrum Extract
RxNorm normalized name: Pyrethrum Extract
DrugBank: Pyrethrum extract (DB11087)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Goldgeist® Forte
Trial: NCT00383942
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol,25 micrograms every 4 hours.
Trial: NCT00358969
Drug: guanfacine (Tenex)
RxNorm normalized name: guanfacine Oral Tablet [Tenex]
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00246246
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00741403
Drug: CPI-613
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
Trial: NCT00732108
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg orally for 2 weeks, then 100mg orally for 6 weeks
Trial: NCT00732108
Drug: lactulose placebo pill
RxNorm normalized name: placebo Pill
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
Trial: NCT01263951
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One 5 mg. tablet daily.
Trial: NCT01263951
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg. twice daily.
Trial: NCT04221997
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)
Trial: NCT00320424
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03422536
Drug: Ficlatuzumab
RxNorm normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02227394
Drug: Z7200
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)
Trial: NCT00527319
Drug: VT-122 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: VT-122 low dose, dose escalated
Trial: NCT00527319
Drug: VT-122 high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT-122 high dose, dose escalated
Trial: NCT00129194
Drug: KP-1461
RxNorm normalized name: KP-1461
DrugBank: KP-1461 (DB05644)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02174861
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection once a month
Trial: NCT06086483
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL 0.5% ropivacaine was injected into the PENG block~20 mL 0.5% ropivacaine was injected into the Adductor Canal block
Trial: NCT06086483
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL 0.9% sodium chloride was injected into the PENG block~20 mL 0.5% sodium chloride was injected into the Adductor Canal block
Trial: NCT01144195
Drug: Panitumumab + FOLFIRI
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.